/PRNewswire/ GenKOre (homepage: www.genkore.com), a biotech start-up in Korea, had a study on the development of hypercompact adenine base editors (ABEs).
DAEJEON, South Korea, Aug. 2, 2022 /PRNewswire/ GenKOre, a biotech start-up in Korea, succeeded in the development of ABEs based on its own hypercompact gene-editing technology and had the relevant study published on Nature Chemical Biology on August 2, 2022. GenKOre (homepage: www.genkore.com) is a business spun off from the Korea Research Institute of Bioscience and Biotechnology (KRIBB), which is a government-invested research institute in Korea. It has platform business through proprietary gene-editing platform. GenKOre succeeded in the development of a hypercompact CRISPR system with AAV delivery compatibility termed TaRGET (Tiny nuclease/augment RNA-based Genome Editing Technology), which was published on Nature Biotechnology in 2021. The AAV-loadable ABE technology was derived from the TaRGET platform. The hypercompact ABEs developed by GenKOre is characterized by compactness in size that can be delivered using AAV and boast of specific and versatile base-editing activity, whi
Dublin, July 15, 2022 (GLOBE NEWSWIRE) The "Synthetic Biology Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027".
“The unregulated advancement of biotech is creating a new arms race and threatening our personal autonomy.” – Spartacus (Article by Rhoda Wilson Republished from Expose-News.com) A document [.]